Bibliographic Details
| Title: |
ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. |
| Authors: |
Zhang L; Authors' Affiliation: Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, Rafique A, Potocky TB, Shan J, Delfino FJ, Shi E, Huang T, Martin JH, Chen G, Macdonald D, Rudge JS, Thurston G, Daly C |
| Source: |
Molecular cancer therapeutics [Mol Cancer Ther] 2014 May; Vol. 13 (5), pp. 1345-55. Date of Electronic Publication: 2014 Mar 14. |
| Publication Type: |
Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: |
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
